

Table SI. Subgroup analysis stratifying patients by TACE exposure.

| Outcome | Non-TACE (n=29) | TACE (n=10) | P-value |
|-----------------------------|-----------------|----------------|---------|
| ORR, n (%) | 11 (37.9) | 3 (30.0) | 0.721 |
| DCR, n (%) | 25 (86.2) | 7 (70.0) | 0.344 |
| Median PFS (95% CI), months | 24.0 (6.5-41.5) | 8.0 (0.0-35.4) | 0.535 |
| Median OS (95% CI), months | Not reached | Not reached | 0.227 |

Non-TACE was defined as 0 treatments with TACE, and TACE was defined as 1 or 2 treatments with TACE. TACE, transarterial chemoembolization; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; CI, confidence interval.